Also Known As:
2-hydroxypropyl methacrylamide; HPMA polymer
Networked: 91 relevant articles (8 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Ghandehari, Hamidreza: 13 articles (05/2015 - 01/2004)
2. Ulbrich, Karel: 13 articles (01/2014 - 08/2003)
3. Kopecková, Pavla: 11 articles (11/2009 - 08/2002)
4. Kopecek, Jindrich: 11 articles (11/2009 - 04/2002)
5. Kopecek, J: 10 articles (03/2008 - 01/2000)
6. Ulbrich, K: 8 articles (08/2014 - 05/2001)
7. Kopecková, P: 8 articles (03/2008 - 01/2000)
8. Ray, Abhijit: 7 articles (05/2015 - 06/2009)
9. Wang, Dong: 7 articles (08/2014 - 01/2007)
10. Chytil, Petr: 7 articles (01/2014 - 12/2005)

Related Diseases

1. Neoplasms (Cancer)
2. Carcinoma (Carcinomatosis)
3. B-Cell Lymphoma (Lymphoma, B Cell)
4. Fever (Fevers)
5. T-Cell Lymphoma (Lymphoma, T Cell)
12/28/2012 - "Biodistribution of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-DOX conjugates of linear and star architectures were compared in EL4 T-cell lymphoma-bearing mice. "
04/23/2002 - "Internalization and subcellular fate of free doxorubicin or its polymeric conjugates based on poly N-(2-hydroxypropyl)methacrylamide (pHPMA), either non-targeted or targeted with anti-Thy1.2 or anti-CD71 monoclonal antibody was tested on EL-4 mouse T-cell lymphoma, SW620 human colorectal carcinoma and OVCAR-3 human ovarian adenocarcinoma. "
01/01/2013 - "Treatment of murine EL4 T cell lymphoma with N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates of doxorubicin (Dox) leads to complete tumor regression and to the development of therapy-dependent longlasting cancer resistance. "
01/17/2002 - "The following data support the concept of the immunomobilizing activity of the N-(2-hydroxypropyl)methacrylamide (HPMA) conjugates: (a) pre-treatment with free drugs (doxorubicin, cyclosporin A) accelerates the appearance of EL4 mouse T-cell lymphoma while a similar pre-treatment with doxorubicin-PHPMA induces limited but definitive mobilization of the host's defense mechanisms; (b) mice cured of EL4 mouse T-cell lymphoma, BCL1 mouse B-cell leukemia and 38C13 mouse B-cell lymphoma by injection of doxorubicin-PHPMA conjugate targeted with monoclonal antibodies (anti-Thy 1.2 for EL4, anti-B1 for BCL1 and anti-CD71 for 38C13) and re-transplanted with a lethal dose of the same cancer cells survive without any treatment considerably longer than control mice; (c) increased NK activity and anti-cancer antibody was detected only in animals treated with doxorubicin-PHPMA conjugate; and (d) considerably increased NK and LAK activity was seen in a human patient treated for generalized breast carcinoma with doxorubicin-PHPMA-IgG."

Related Drugs and Biologics

1. hydroxypropyl methacrylate
2. Doxorubicin (Adriamycin)
3. meso-chlorin e(6) monoethylene diamine
4. Dexamethasone (Maxidex)
5. 1-phenyl-3,3-dimethyltriazene (PDT)
6. Polymers
7. Gold
8. Cyclosporine (Ciclosporin)
9. Transferrin (beta 2 Transferrin)
10. Transferrin Receptors (Transferrin Receptor)

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Drug Therapy (Chemotherapy)
3. Photochemotherapy (Photodynamic Therapy)
4. Therapeutics
5. Combination Drug Therapy (Combination Chemotherapy)